Clinical trials: Malaria, completed
Malaria
Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Efavirenz
This study assessed the effect of multiple doses of a moderate inducer of cytochrome P450 (CYP) 3A4 (efavirenz) on the pharmacokinetics (PK) of ganaplacide and lumefantrine combination.
- Trial name
- NCT05330273
- Testing
- Ganaplacide, Lumefantrine, Efavirenz
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Falciparum Malaria
Phase Ib Trial of Two Virosome Formulated Malaria Vaccine Components (PEV 301, PEV 302) in Tanzania
This is a phase Ib double-blind randomized placebo controlled age-deescalating trial to assess sagety and immunogenicity of two virosome formulated anti-malaria vaccine components (PEV 301 and PEV 302) administered in combination…
- Trial name
- PMAL03 (NCT00513669)
- Testing
- PEV 301& 302 in virosomes, Inflexal V (active comparator)
- Where
- Tanzania
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Swiss Tropical & Public Health Institute
Malaria
Safety, Tolerability and Protective Efficacy of PfSPZ Vaccine in Gabonese Children
This study is a single site, randomized, double-blind, placebo-controlled trial. The trial will assess the safety, tolerability, immunogenicity and vaccine efficacy (VE) of PfSPZ Vaccine in Gabonese children that are naturally…
- Trial name
- NCT03521973
- Testing
- PfSPZ Vaccine, Normal Saline
- Where
- Gabon
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria
Assessment of Safety and Immunogenicity of R21/Matrix-M™ in African Children Living With HIV
A Phase Ib trial to evaluate the safety and immunogenicity of R21/Matrix-M™ in African children living with HIV
- Trial name
- NCT05385510
- Testing
- R21/Matrix-M™
- Where
- Uganda
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
Trial to Evaluate L9LS in Healthy Adults
Background: Malaria is a parasitic disease carried by mosquitoes in tropical areas. There is no vaccine to prevent malaria infection. If not treated right away, it can become serious or deadly.
- Trial name
- VRC 614 (NCT05019729)
- Testing
- VRC-MALMAB0114-00-AB, Plasmodium falciparum (P. falciparum) sporozoite challenge
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria,Falciparum, Feasibility
Malaria Vaccine Pilot Evaluation
The RTS,S/AS01 malaria vaccine is being introduced sub-nationally in phased pilot introductions through the EPI programmes in Malawi Ghana and Kenya.
- Conditions
- Malaria,Falciparum, Feasibility, Safety, Mortality
- Trial name
- MVPE (NCT03806465)
- Testing
- Feasibility survey, Sentinel hospital surveillance, Community mortality surveillance
- Where
- 3 sites in Ghana, Kenya and 1 more
- Volunteers
- 30,124 people, healthy volunteers welcome
- Sponsor
- Rafiq OKINE
Fever
Filter Paper Blood Spots Collected During Fever as a Source for Post-travel Diagnosis in Travelers
This study is part of a larger prospective cohort study (JOKA), designed to study febrile illness occurring during a travel to the tropics, as well as the evaluation of the clinical use of malaria rapid diagnostic tests (RDT) by…
- Trial name
- JOKA-II (NCT02900066)
- Where
- Belgium
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Plasmodium Falciparum Malaria
AMA1-C1/Alhydrogel + CpG 7909 for Malaria
The purpose of this study is to test an experimental malaria vaccine in about 75 healthy adults, 18-45 years of age. The study will also test an experimental adjuvant which is a material added to a vaccine to help the body make…
- Trial name
- NCT00344539
- Testing
- AMA1-C1/Alhydrogel®, CPG 7909 Oligodeoxynucleotide (VaxImmune®)
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Anaemia in Children
Study on Preventing Anemia in Children in Ghana
A study that seeks to establish an effective way of preventing anaemia in children at the community level using two known interventions - Iron supplementation and or antimalarial.
- Trial name
- NCT00301054
- Testing
- Ferrous sulphate, Sulphadoxine-Pyrimethamine
- Where
- Ghana
- Volunteers
- 872 people, healthy volunteers welcome
- Sponsor
- Ghana Health Services
Malaria
A Study to Evaluate the Safety, Immunogenicity and Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Malaria Vaccine RTS,S/AS02A, When Administered to Children Aged 1 to 4 Years Living in a Malaria-endemic Region of Mozambique.
Malaria is an important cause of death and serious illness among Mozambican children. Although the risk of malaria can be reduced by drugs and by impregnated bed nets, it would be helpful if children could be protected against…
- Trial name
- NCT00197041
- Testing
- RTS,S/AS02A
- Where
- Mozambique
- Volunteers
- 2,022 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Plasmodium Falciparum Infection
Trial to Evaluate the Safety, Immunogenicity and Protective Efficacy of Three or Five Administrations of GAP3KO Sporozoites
This Phase 1 trial will include 16 subjects who will receive the Genetically-attenuated p52-/p36-/sap1- Plasmodium falciparum Parasites (GAP3KO) vaccine administered by the bite of approximately 200 infected Anopheles stephensi…
- Trial name
- NCT03168854
- Testing
- Genetically-attenuated p52-/p36-/sap1- Plasmodium falciparum parasite (GAP3KO) strain, Malaria challenge
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Malaria,Falciparum
Safety and Efficacy of R0.6C Vaccine
This is a first-in-human phase I, open-label, single-site, dose escalation study to determine the safety, tolerability and Plasmodium falciparum transmission reducing activity of the R0.6C vaccine in two different adjuvant…
- Trial name
- STOP-TRANS (NCT04862416)
- Testing
- R0.6C transmission blocking vaccine
- Where
- Netherlands
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Malaria
MMV390048 and Its Antimalarial Activity Against Plasmodium Falciparum in Healthy Adult Subjects, Part B
Pharmacodynamic profiling will also be studied to characterize the effects of MMV390048 on P. falciparum clearance kinetics in healthy subjects using the Induced Blood Stage Malaria (IBSM) challenge model to determine the minimum…
- Trial name
- NCT02783833
- Testing
- MMV390048 40mg, MMV390048 dose to be determined mg
- Where
- Australia
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria Prophylaxis
A Phase 1 Study To Estimate The Relative Bioavailability Of Co-Administered Formulations Of Azithromycin Microsphere And Chloroquine Test Formulation Compared With Co-Administered Immediate Release Individual Azithromycin And Chloroquine Tablets In Healthy Adult Subjects
Estimate the relative bioavailability of co-administered azithromycin microsphere (2000 mg) and the chloroquine (620 mg CQ base) test formulation compared to co-administered immediate release individual tablets of azithromycin…
- Trial name
- AZCQ (NCT01100060)
- Testing
- azithromycin (AZ) microsphere, test chloroquine (CQ) formulation, azithromycin (AZ)
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Pfizer
Malaria
Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax
This is a randomized, double-blind, controlled, which seeks to compare two groups of volunteers (naive and previously exposed to malaria) who were made 3 immunizations with a synthetic derivative of the CS protein of Plasmodium…
- Trial name
- NCT02083068
- Testing
- Vaccine PvCS N+C+R, Vaccine PvCS N+C, SSN Montanide ISA-51
- Where
- Colombia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Malaria Vaccine and Drug Development Center
HIV Infections, Malaria
Drug Interaction Study Between Atovaquone and Antiretroviral Agents in HIV-1 Infected Patients
Malarone® (atovaquone/proguanil) is frequently used in malaria prophylaxis. Unfortunately, there are indications that certain anti-HIV agents may decrease atovaquone plasma levels by induction of atovaquone metabolism.
- Trial name
- NCT00421473
- Testing
- Atovaquone / Proguanil
- Where
- 5 sites in Netherlands
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Malaria, Pregnancy Malaria
LAMP Detection of Malaria in PREGnancy (LAMPREG) Trial
Objective: The aim of this study is to evaluate the impact of enhanced malaria cases detection using molecular testing (LAMP) on maternal and infant morbidity and mortality in a prospective study design.
- Conditions
- Malaria, Pregnancy Malaria, Malaria in Pregnancy
- Trial name
- LAMPREG (NCT03754322)
- Testing
- LAMP, Microscopy/RDT
- Where
- 4 sites in Canada, Ethiopia
- Volunteers
- 2,424 people, healthy volunteers welcome
- Sponsor
- University of Calgary
Malaria
VAC063C: A Study to Assess Repeat Blood-stage P. Falciparum Infection
This is a clinical study to assess the safety of primary, secondary and tertiary blood-stage controlled human Plasmodium falciparum malaria infection of healthy malaria-naïve UK adults, as well as to evaluate any effect of prior…
- Trial name
- NCT03906474
- Testing
- Blood-stage controlled human P. falciparum malaria infection
- Where
- United Kingdom
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria, Vivax
Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1
This is an Open label, first-in-human, Phase I/IIa, blood-stage P. vivax malaria vaccine trial to assess the safety, immunogenicity and efficacy of the blood-stage Plasmodium vivax malaria vaccine candidate PvDBPII in Matrix M1…
- Trial name
- NCT04201431
- Testing
- PvDBPII/Matrix-M1
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
School Based Malaria Control in Ugandan Schoolchildren
The investigators hypothesize that schoolchildren treated with IPT using DP over one year of follow-up will have a different risk of clinical malaria compared to those treated with placebo.
- Trial name
- SBMC (NCT01231880)
- Testing
- Four monthly IPT with dihydroartemisinin Piperaquine (DP), Monthly IPT using DP
- Where
- Uganda
- Volunteers
- 740 people, healthy volunteers welcome
- Sponsor
- Makerere University